Bexsero is a vaccine used to protect individuals from the age of two months against invasive meningococcal disease caused by one group of the bacterium Neisseria meningitidis (group B). Invasive disease occurs when the bacteria spread through the body causing serious infections such as meningitis (infection of the membranes that surround the brain and spine) and septicaemia (blood infection). Bexsero contains parts of the bacteria N. meningitidis group B.
Therapeutic Indication
### Therapeutic indication Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains.
Therapeutic Area (MeSH)
ATC Code
J07AH09
ATC Item
meningococcus B, multicomponent vaccine
Pharmacotherapeutic Group
Meningococcal vaccines
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| recombinant Neisseria meningitidis group B fHbp fusion protein | N/A | Neisseria meningitidis serogroup b fhbp fusion protein antigen |
| outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254) | N/A | Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle |
| recombinant Neisseria meningitidis group B NadA protein | N/A | Neisseria meningitidis serogroup b nada protein antigen |
| recombinant Neisseria meningitidis group B NHBA fusion protein | N/A | Neisseria meningitidis serogroup b nhba fusion protein antigen |
EMA Name
Bexsero
Medicine Name
Bexsero
Aliases
N/ANo risk management plan link.
